Scholar Rock

Scholar Rock

Biotechnology
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

$6.7B

Market Cap • 9/11/2026

2017

(9 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

26,4

P/S

P/EBITDA

P/OCF

P/FCF

P/E

BVPS

2,1

EPS

Market Cap

Market Cap

6,7B

EV

6,4B

EV/Revenue

0

EV/EBITDA

-15,8

EV/EBIT

-15,8

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-5,3%

Total Yield

-5,3%

Payout

0%

Retained Earnings

-1,5B

Profitability

Gross Margin

EBITDA Margin

EBIT Margin

Net Margin

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

12,5%

Capex/OCF

-0,1%

SBC/OCF

% PPE

1,9%

% Goodwill

0%

ROE

ROIC

Growth

CAGR Revenue 5Y

-100%

CAGR Op. Income 5Y

30,5%

CAGR Net Income 5Y

30,4%

CAGR EPS 5Y

0,9%

CAGR OCF 5Y

24%

Leverage

N.D./EBITDA

0,7

Debt/Equity

0%

Current Ratio

7

Quick Ratio

6,8

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium